The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now
The test ($99 add-on, $298 standalone) reveals genetic predispositions in metabolic pathways that influence weight loss capacity and insulin sensitivityfactors affecting lipid response
Reported side effects have been gastrointestinal symptoms, such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort
Psychosocial stress and overweight and obesity: findings from the Chicago Community Adult Health Study
Retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) produces diarrhea in approximately 34% of users at 12 mg, compared to roughly 30% for semaglutide at 2.4 mg
Many individuals focus on building a foundation around multivitamin support, protein intake, hydration, and electrolyte balance
